Systematic Reviews
Copyright ©The Author(s) 2015.
World J Rheumatol. Jul 12, 2015; 5(2): 108-126
Published online Jul 12, 2015. doi: 10.5499/wjr.v5.i2.108
Table 2 Characteristics of included studies
NstudyRef.Type of studyTime horizonPatientInterventionCountry conducting the studyFunding SourcesDuration of the study (mo)Follow-up (mo)
1Geborek et al[12]CohortProspectiveNaiveETA vs IFX vs LEFSwedenNR2412
2Van Vollenhoven et al[13]RegistryProspectiveNRETA vs ETA + MTXSwedenMixedNR12
3Cohen et al[14]CohortRetrospectiveTherapeutic failureIFX vs ETAFranceNR483
4Finckh et al[15]RegistryProspectiveMixedADA vs ETA vs IFXSwitzerlandMixed8012
5Heiberg et al[16]CohortProspectiveMixedADA monotherapy vs ADA + MTXNorwayMixedNR12
6Hyrich et al[17,18]RegistryProspectiveNRETA monotherapy vs ETA + MTX vs ETA + DMARD and ADA monotherapy vs ADA + MTX vs ADA + DMARDEnglandPharmaceutical industryNR6
7Kristensen et al[19]CohortProspectiveNaiveETA vs IFXSwedenMixed5536
8Bernal Rivera et al[20]CohortProspectiveNaiveADA vs ETA vs IFXSpainNR2412
9Kristensen et al[19]CohortProspectiveNaiveETA vs IFXSpainNR726
10Radstake et al[23]CohortProspectiveNRIFX vs ADAThe NetherlandsMixedNR6
12Bazzani et al[24]RegistryProspectiveMixedADA vs ETA vs IFXItalyPharmaceutical industry25.2936
13Greenwood et al[47]CohortRetrospectiveNRADA vs ETA vs IFXEnglandNRNR12
14Laas et al[25]CohortProspectiveNaiveETA vs ADAFinlandNo pharmaceutical industry363
15Arenere Mendoza et al[26]CohortRetrospectiveMixedADA vs ETA vs IFXSpainNR8012
16Buch et al[46]CohortProspectiveTherapeutic failureRTX vs anti-TNFEnglandNRNR6
17Canhão et al[27]RegistryProspectiveNaiveADA vs ETA vs IFXPortugalMixedNR12
18Hetland et al[28]RegistryProspectiveNaiveADA vs ETA vs IFXDenmarkMixed8612
19Blom et al[29]RegistryProspectiveTherapeutic failureRTX vs anti-TNFThe NetherlandsMixedNR12
20Chatzidionysiou et al[30]RegistryProspectiveMixedRTX monotherapy vs RTX + MTX vs RTX + LEFEuropePharmaceutical industryNR12
21Gotenberg et al[45]RegistryProspectiveMixedRTX vs ABATFranceNRNR6
22Iannone et al[32]RegistryProspectiveNRADA vs ETA vs IFXItalyNRNR48
23Leffers et al[33]RegistryProspectiveMixedABAT vs TOCIDenmarkMixedNR48
24Martínez-Pérez et al[44]CohortRetrospectiveMixedRTX vs IFXSpainNRNR12
25Wakabayashi et al[34]CohortRetrospectiveTherapeutic failureTOCI vs ETAJapanNo pharmaceutical industry6012
26Finckh et al[36]CohortProspectiveTherapeutic failureRTX vs anti-TNFSwitzerlandMixedNR24
27Gomez-Reino et al[35]CohortProspectiveTherapeutic failureRTX vs anti-TNFSpainPharmaceutical industry3612
28Greenberg et al[37]RegistryProspectiveNaiveADA vs ETA vs IFXUnied StatesMixed7424
29Kekow et al[38]CohortRetrospectiveTherapeutic failureRTX vs anti-TNFGermanyPharmaceutical industryNR6
30Schabert et al[39]CohortRetrospectiveNRADA vs ETA vs IFXUnied StatesMixed1512
31Chatzidionysiou et al[40]RegistryProspectiveTherapeutic failureAnti-TNF vs ETA vs ADAStockholmNRNR6
32Keystone et al[43]CohortRetrospectiveTherapeutic failureABAT vs TOCICanadaNRNR12
33Emery et al[41]CohortProspectiveTherapeutic failureRTX vs anti-TNFMulticentreMixedNR12
34Flouri et al[42]RegistryProspectiveMixedADA vs ETA vs IFXGreeceMixed6012
35Harrold et al[31]RegistryProspectiveTherapeutic failureABAT vs TOCIUnied StatesMixedNR12